- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04428554
Consolidative Radiotherapy for Metastatic Urothelial Bladder Cancer Patients Without Progression and With no More Than Three Residual Metastatic Lesions Following First Line Systemic Therapy (BLAD-RAD01)
Consolidative Radiotherapy for Metastatic Urothelial Bladder Cancer Patients Without Progression and With no More Than Three Residual Metastatic Lesions Following First Line Systemic Therapy: a Prospective Randomized Comparative Phase II Trial
This is a phase II, multicenter, randomized open-label and comparative study designed to evaluate whether local consolidative radiotherapy plus standard of care improves overall survival as compared to standard of care in patients with limited metastatic urothelial bladder cancer and without progression following the initial phase of first-line systemic therapy.
Each patient will be followed during 4 years from the date of randomization.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Jonathan KHALIFA
- Phone Number: 05 31 15 54 01
- Email: khalifa.jonathan@iuct-oncopole.fr
Study Locations
-
-
-
Albi, France
- Recruiting
- Clinique Claude Bernard
-
Contact:
- Laurent VOTRON
- Phone Number: 05 63 77 77 56
- Email: votron@claude-bernard-albi.com
-
Angers, France
- Recruiting
- Institut de Cancérologie de l'Ouest
-
Contact:
- Nathalie MESGOUEZ-NEBOUT
- Phone Number: 02 41 35 27 00
- Email: thalie.mesgouez-nebout@ico-unicancer.fr
-
Besançon, France
- Recruiting
- CHU Besançon
-
Contact:
- Jihane BOUSTANI
- Phone Number: 03 70 63 23 23
- Email: jboustani@chu-besançon.fr
-
Bordeaux, France
- Recruiting
- Institut Bergonie
-
Contact:
- Paul SARGOS
- Phone Number: 05 56 33 33 33
- Email: P.Sargos@bordeaux.unicancer.fr
-
Brest, France
- Recruiting
- CHU Morvan
-
Contact:
- Ulrike SCHICK
- Email: ulrike.schick@chu-brest.fr
-
Brest, France
- Recruiting
- Clinique Pasteur-Lanroze
-
Contact:
- Matthieu CHASSERAY
- Phone Number: 02 98 31 30 07
- Email: m.chasseray@oncologie-brest.fr
-
Caen, France
- Recruiting
- Centre François Baclesse
-
Contact:
- Pierre-Emmanuel BRACHET
- Phone Number: 02 31 45 50 02
- Email: pe.brachet@baclesse.unicancer.fr
-
Clermont-Ferrand, France
- Withdrawn
- Centre Jean Perrin
-
Dunkerque, France
- Recruiting
- Institut Andrée Dutreix
-
Contact:
- Thomas MULLIEZ
- Phone Number: 03 28 51 96 30
- Email: thomasmulliez@hotmail.com
-
Lille, France
- Not yet recruiting
- Centre Oscar Lambret
-
Contact:
- David PASQUIER
- Phone Number: 03 20 29 51 44
- Email: d-pasquier@o-lambret.fr
-
Marseille, France
- Recruiting
- Institut Paoli-Calmettes
-
Contact:
- Naji SALEM
- Phone Number: 04 91 22 36 37
- Email: salemn@ipc.unicancer.fr
-
Nice, France
- Recruiting
- Centre Antoine Lacassagne
-
Contact:
- Médéric BARRET
- Phone Number: 04 92 03 12 60
- Email: mederic.barret@nice.unicancer.fr
-
Paris, France
- Recruiting
- Institut Curie
-
Contact:
- Gilles CREHANGE
- Phone Number: 01 72 38 94 45
- Email: gilles.crehange@curie.fr
-
Pau, France
- Withdrawn
- Groupement de Radiothérapie et d'Oncologie des Pyrénées
-
Saint-Herblain, France
- Recruiting
- Institut de Cancérologie de l'Ouest
-
Contact:
- Valentine GUIMAS
- Phone Number: 02 40 57 99 55
- Email: valentine.guimas@ico.unicancer.fr
-
Saint-Mandé, France
- Recruiting
- Hia Begin
-
Contact:
- Hugo PICCHI
- Phone Number: 01 86 93 75 20
- Email: picchi.hugo90@gmail.com
-
Saint-Priest-en-Jarez, France
- Not yet recruiting
- Institut de Cancérologie Lucien Neuwirth
-
Contact:
- Nicolas MAGNE
- Phone Number: 04 77 91 74 25
- Email: nicolas.magne@icloire.fr
-
Toulouse, France
- Recruiting
- Institut Universitaire du Cancer Toulouse Oncopole
-
Contact:
- Jonathan KHALIFA
- Phone Number: 05 31 15 54 29
- Email: khalifa.jonathan@iuct-oncopole.fr
-
Villejuif, France
- Recruiting
- Institut Gustave Roussy
-
Contact:
- Pierre BLANCHARD
- Phone Number: 01 42 11 44 13
- Email: pierre.blanchard@gustaveroussy.fr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age ≥ 18 years
- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
- Urothelial bladder cancer histologically proven (both pure urothelial cancers and mixed histologic features are allowed)
- Metastatic patients (AJCC v8: M1a or M1b) documented with contrast-enhanced CT-scanner of the chest, abdomen and pelvis, either de novo or presenting first distant relapse following cystectomy (with no local recurrence in the cystectomy bed)
- Completion of the initial phase (4-6 cycles) of 1st line metastatic treatment (systemic therapy by chemotherapy and/or immunotherapy by immune check-point inhibitor according to standard recommendations). Patients having started maintenance therapy are eligible.
- No disease progression after the initial phase of first-line metastatic systemic therapy according to RECIST v1.1
No more than 3 residual metastatic lesions following the initial phase of first-line metastatic systemic therapy:
The number of residual lesions is determined on the basis of the imaging modality for tumor response assessment performed after systemic treatment according to local habits (CT-scan or 18FDG PET-CT if performed):
In case of response assessment by CT-scanner only: residual lesions are all remaining visible lesions
In case of response assessment by additional 18FDG PET-CT: residual lesions are only the lesions with residual hyperfixation
- Regarding distant lymph nodes metastases:
If evaluation is performed by CT-scanner only, residual lymph nodes are considered pathological according to one or several criteria among:
- Short axis ≥ 1cm
- Central necrosis
- Heterogeneous contrast enhancement
Residual para-aortic nodes involvement accounts for one lesion, even if several para-aortic nodes are involved.
Other nodes: each involved node accounts for one lesion.
- Residual metastases (if applicable) eligible for SBRT in terms of dose constraints to the organs at risk, with no prior radiotherapy interfering with SBRT
- 8 weeks or less between last cycle of the initial phase of systemic treatment and randomization
- No contraindication to pelvic radiotherapy
- Signed informed consent
- Patient able to participate and willing to give informed consent prior performance of any study-related procedures and to comply with the study protocol
- Patient affiliated to a Social Health Insurance in France.
Exclusion Criteria:
- Non-transitional cell histology (Squamous cell carcinoma, adenocarcinoma or neuroendocrine carcinoma of the bladder)
- Brain metastases before systemic treatment
- Liver metastases before systemic treatment
- Absence of target to be irradiated (i.e. previous cystectomy + no residual lesions following systemic treatment + no pelvic or para-aortic nodes at metastatic presentation)
- Patient with relapse following definitive chemoradiation of the bladder
- Local recurrence in the cystectomy bed following cystectomy
- Previous pelvic irradiation
- Prior radiotherapy near the residual metastatic lesions precluding ablative SBRT
- Active inflammatory bowel disease
- Contraindication to SBRT of a lesion due to organ dysfunction; in particular, patients with lung lesions and documented or suspected interstitial lung disease should not be included
- History of scleroderma
- Current or past history of second neoplasm diagnosed within the last 5 years (except basocellular carcinoma and prostate cancer incidentally discovered during previous cystoprostatectomy and pelvic lymph node dissection and with a good prognosis [T stage <pT3b and Gleason <8 and pN- and post-operative PSA <0.1 ng/mL])
- Pregnancy or breast feeding or inadequate contraceptive measures
- Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial
- Any psychological, familial, geographic or social situation, according to the judgment of investigator, potentially preventing the provision of informed consent or compliance to study procedure
- Patient who has forfeited his/her freedom by administrative or legal award or who is under legal protection (curatorship and guardianship, protection of justice)
- Concurrent enrolment in another interventional therapeutic clinical study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Experimental arm
|
Consolidative radiotherapy (pelvic irradiation and/or metastases irradiation) + standard of care +/- previous transurethral resection of bladder tumor
|
No Intervention: Control arm
Standard of care
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Overall Survival
Time Frame: 4 years for each patient
|
4 years for each patient
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Progression Free Survival
Time Frame: 4 years for each patient
|
4 years for each patient
|
Safety will be assessed by the toxicity grading of the National Cancer Institute (NCI-CTCAE v5)
Time Frame: 4 years for each patient
|
4 years for each patient
|
Quality of life will be evaluated by the EORTC QLQ-C-30 questionnaire
Time Frame: 4 years for each patient
|
4 years for each patient
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 19 URO 15
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Urothelial Bladder Cancer
-
Beijing InnoCare Pharma Tech Co., Ltd.RecruitingBladder Urothelial CancerChina
-
Sandy SrinivasGlaxoSmithKlineCompletedBladder Cancer | Bladder (Urothelial, Transitional Cell) Cancer | Bladder (Urothelial, Transitional Cell) Cancer Resectable (Pre-Cystectomy) | Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive) | Bladder (Urothelial, Transitional Cell) Cancer Metastatic or UnresectableUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI); National Institute for Biomedical Imaging...TerminatedStage II Bladder Urothelial Carcinoma | Stage IV Bladder Urothelial Carcinoma | Stage III Bladder Urothelial Carcinoma | Bladder Papillary Urothelial Carcinoma | Stage 0a Bladder Urothelial Carcinoma | Stage 0is Bladder Urothelial Carcinoma | Stage I Bladder Cancer With Carcinoma In Situ | Stage...United States
-
M.D. Anderson Cancer CenterRecruitingMetastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Recurrent Bladder Urothelial Carcinoma | Recurrent Renal Pelvis Urothelial Carcinoma | Recurrent... and other conditionsUnited States
-
National Cancer Institute (NCI)Active, not recruitingAdvanced Bladder Urothelial Carcinoma | Advanced Ureter Urothelial Carcinoma | Metastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Recurrent Bladder... and other conditionsUnited States
-
National Cancer Institute (NCI)RecruitingMetastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Stage IV Bladder Cancer AJCC v8 | Stage IV Renal Pelvis Cancer AJCC v8 | Stage IV Ureter Cancer... and other conditionsUnited States
-
National Cancer Institute (NCI)RecruitingMetastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Recurrent Bladder Urothelial Carcinoma | Recurrent Renal Pelvis Urothelial Carcinoma | Recurrent... and other conditionsUnited States
-
National Cancer Institute (NCI)Active, not recruitingMetastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Recurrent Bladder Urothelial Carcinoma | Recurrent Renal Pelvis Urothelial Carcinoma | Recurrent Ureter Urothelial Carcinoma and other conditionsUnited States
-
Stanford UniversityAstraZenecaTerminatedBladder Adenocarcinoma | Bladder Mixed Adenocarcinoma | Bladder Squamous Cell Carcinoma | Infiltrating Bladder Urothelial Carcinoma With Giant Cells | Infiltrating Bladder Urothelial Carcinoma, Nested Variant | Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant | Bladder Urothelial... and other conditionsUnited States
-
IRCCS San RaffaeleRecruitingBladder Cancer | Bladder Disease | Bladder Cancer Recurrent | Bladder Urothelial Carcinoma | Non Muscle Invasive Bladder Cancer | Bladder Neoplasm | Non-Muscle Invasive Bladder Urothelial Carcinoma | Non-Muscle Invasive Bladder Neoplasms | Bladder Cancer Stage I, With Cancer in Situ | Bladder Urothelial... and other conditionsItaly
Clinical Trials on Experimental arm
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingHPV | Related Malignancy | Related CarcinomaUnited States
-
Tata Memorial HospitalRecruiting
-
Le Mans UniversiteActive, not recruiting
-
Centre hospitalier de l'Université de Montréal...RecruitingHead and Neck Cancer | Oligoprogressive | Metastatic CancerCanada
-
University Hospital, BrestNot yet recruiting
-
Qure Healthcare, LLCProgenity, Inc.CompletedPre-EclampsiaUnited States
-
Qure Healthcare, LLCEthos LaboratoriesCompletedPain | Pain, ChronicUnited States
-
University of California, San FranciscoNational Cancer Institute (NCI)Completed
-
Assistance Publique - Hôpitaux de ParisRecruitingCerebral Small Vessel DiseasesFrance
-
Institut du Cancer de Montpellier - Val d'AurelleCompletedMetastatic Ovarian CancerFrance